TEM1657 possesses very favorable features at pre-clinical stage,
making it a very promising therapeutic solution for psoriasis patients.
Very strong and rapid ability to alleviate psoriasis symptoms
Good safety profile
Stable at room temperature
Temisis uses a phenotypic cell-based assay to screen extensive libraries of compounds to identify first-in-class small molecules with high potential. This screening assay along with lead optimization allowed to discover TEM1657 and TEM1648.
Clinical trials are to start in 2023
TEM1648 is another asset in development to treat psoriasis.
TEM1657‘s future indications are atopic dermatitis, and Crohn’s disease.